Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Tipranavir (TPV) is a nonpeptidic HIV-1 protease inhibitor manufactured by Boehringer Ingelheim under the trade name Aptivus. It is used as part of combination antiretroviral therapy for treatment-experienced patients with HIV-1 infection whose virus is resistant to more than one protease inhibitor. It is not approved for treatment-naïve patients.
Art & Overview
Explore the main themes, entities and connections around Tipranavir. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
patients protease drug hiv-1 aptivus inhibitor ritonavir hepatotoxicity used combination antiretroviral therapy treatment-experienced resistant approved resistance june salvage current side
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Tipranavir | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Tipranavir | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Tipranavir | ATC code | J05AE09 (WHO) | 1.00 | infobox |
| Tipranavir | CAS Number | 174484-41-4 Y | 1.00 | infobox |
| Tipranavir | ChEMBL | ChEMBL183041 N | 1.00 | infobox |
| Tipranavir | ChemSpider | 10482313 Y | 1.00 | infobox |
| Tipranavir | CompTox Dashboard (EPA) | DTXSID6048622 | 1.00 | infobox |
| Tipranavir | DrugBank | DB00932 Y | 1.00 | infobox |
| Tipranavir | ECHA InfoCard | 100.158.066 | 1.00 | infobox |
| Tipranavir | Elimination half-life | 4.8–6 hours | 1.00 | infobox |
| Tipranavir | Excretion | Feces (82.3%), urine (4.4%) | 1.00 | infobox |
| Tipranavir | Formula | C31H33F3N2O5S | 1.00 | infobox |
| Tipranavir | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Tipranavir | Legal status | US: ℞-only | 1.00 | infobox |
| Tipranavir | Legal status | EU: Rx-only | 1.00 | infobox |
| Tipranavir | License data | EU EMA: by INN | 1.00 | infobox |
| Tipranavir | License data | US DailyMed: Tipranavir | 1.00 | infobox |
| Tipranavir | License data | US FDA: Tipranavir | 1.00 | infobox |
| Tipranavir | MedlinePlus | a606009 | 1.00 | infobox |
| Tipranavir | Metabolism | Liver | 1.00 | infobox |
| Tipranavir | Molar mass | 602.67 g·mol−1 | 1.00 | infobox |
| Tipranavir | NIAID ChemDB | 032941 | 1.00 | infobox |
| Tipranavir | PDB ligand | TPV (PDBe, RCSB PDB) | 1.00 | infobox |
| Tipranavir | Pregnancy category | AU: B3 | 1.00 | infobox |
| Tipranavir | Pronunciation | /tɪpˈrænəvɪər/ tip-RAN-ə-veer | 1.00 | infobox |
| Tipranavir | Protein binding | 99.9% | 1.00 | infobox |
| Tipranavir | PubChem CID | 54682461 | 1.00 | infobox |
| Tipranavir | Routes of administration | By mouth (soft capsules) | 1.00 | infobox |
| Tipranavir | Trade names | Aptivus (AP-tiv-əs) | 1.00 | infobox |
| Tipranavir | UNII | ZZT404XD09 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.